Kestrel

Send Away Test for Oncotype DX Breast Recurrence Score

Gloucestershire Hospitals NHS Foundation Trust · published Thu 8 Oct 2026

In plain English

Reading the notice and writing a summary. This takes a few seconds the first time.

The notice doesn't say where the documents are, but Gloucestershire Hospitals NHS Foundation Trust's other tenders use health-family.force.com. Register there (it's free) and look for this tender, or email the buyer's contact on the notice.

The notice as published

Provision of Oncotype DX Breast Recurrence Score via a genomic assay that provides a personalised insight into an individual patient's breast cancer biology. Oncotype DX Breast Recurrence Score is a genomic assay that provides a personalised insight into an individual patient’s breast cancer biology. The Oncotype DX Breast Recurrence Score test addresses the issue overtreatment with chemotherapy, particularly for patients with lymph node-positive breast cancer. In providing a more precise information about tumour biology, it allows many patients to avoid unnecessary chemotherapy. Due to Exact Science being the only provider of this test, the contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023 Direct Award A. The lifetime of the contract is £229,500 from 1st July 2027 until 30th June 2028